Steven M. Fruchtman - Mar 13, 2024 Form 4 Insider Report for Onconova Therapeutics, Inc. (ONTX)

Role: PRESIDENT, CHIEF EXECUTIVE OFF, Director
Signature: /s/ Mark Guerin, Attorney-in-Fact
Stock symbol: ONTX
Transactions as of: Mar 13, 2024
Transactions value $: -$7,854
Form type: 4
Date filed: 3/15/2024, 05:36 PM
Previous filing: Feb 9, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ONTX	Common Stock	Options Exercise		+23.1K	+38.26%		83.5K	Mar 13, 2024	Direct	F1
transaction	ONTX	Common Stock	Tax liability	-$7.85K	-8.73K	-10.45%	$0.90	74.8K	Mar 14, 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ONTX	Restricted Stock Units	Options Exercise	$0	-23.1K	-33.33%	$0.00	46.2K	Mar 13, 2024	Common Stock	23.1K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	On March 13, 2023 the reporting person was granted 69,333 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.